Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
ID: 357204Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $350K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357204

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-095.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)." This initiative aims to support applications that propose secondary data analysis and integration of existing datasets to better understand cancer risk factors and related outcomes, including survival and treatment responses. The program emphasizes the importance of leveraging clinical, genomic, lifestyle, and environmental data to address significant scientific questions in cancer research. Interested applicants can apply for grants with a maximum budget of $350,000 per year, with a project duration of up to five years. The application deadline is September 7, 2026, and further details can be obtained by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-095.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-095-Full-Announcement.html
    PAR-25-095.html
    The National Cancer Institute (NCI), alongside key NIH branches, has released a Notice of Funding Opportunity (NOFO) aimed at supporting secondary analysis of existing datasets to unravel cancer risks and related outcomes. The initiative encourages innovative analyses of clinical, genomic, lifestyle, and environmental data, aiming to enhance understanding of cancer etiology, survival, and treatment responses. Key objectives include identifying cancer risk factors, improving prevention strategies, and fostering methodological advancements in cancer research. Applicants are prompted to leverage current datasets and adopt new analytical methods while adhering to strict funding limits and research guidelines. The maximum project duration is five years, with an annual budget capped at $350,000. Eligible organizations encompass higher education institutions, non-profits, and government entities, and partnerships are encouraged to utilize various publicly available data resources. The project underscores the NIH's commitment to data sharing and integration as vital components of cancer research advancement while ensuring compliance with rigorous federal requirements.
    Similar Opportunities
    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a Notice of Funding Opportunity (NOFO) titled "Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes" (PAR-23-254). This initiative aims to encourage researchers to conduct innovative analyses of existing datasets, including clinical, genomic, and epidemiological data, to address critical questions related to cancer risk, treatment responses, and health outcomes. By leveraging previously collected data, the program seeks to enhance understanding of cancer-related issues while allowing for a limited generation of new data for validation purposes. Eligible applicants include a wide range of institutions, with funding capped at $350,000 annually for up to five years. Applications will be accepted from October 2023 until June 2026, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)." This initiative encourages applications that propose innovative secondary data analyses and integration of existing datasets to address significant scientific questions related to cancer risk, prevention, and treatment outcomes. The program aims to leverage diverse data sources, including clinical, environmental, and genomic datasets, to enhance understanding of cancer and improve public health strategies. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofit organizations, and tribal governments, with a maximum funding amount of $200,000 and a project duration of up to two years. Interested parties can find more information and application details at the NIH grants website, with the submission deadline set for September 7, 2026.
    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity for secondary analysis and integration of existing datasets to elucidate cancer risk and related outcomes. This initiative encourages innovative research that leverages existing clinical, genomic, and epidemiological data to address critical questions in cancer control, with a focus on risk prediction, survival, and treatment responses. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and foreign entities, with a budget cap of $275,000 over a two-year period. Applications are due by September 7, 2026, and interested parties can find more information and contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-255.html.
    Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies." This initiative aims to support innovative research projects that investigate the adverse effects of cancer therapies, particularly those that lead to chronic comorbidities or delayed sequelae, with a focus on understanding the underlying mechanisms and developing therapeutic strategies to mitigate these long-term issues. The funding is open to a diverse range of applicants, including educational institutions, non-profits, and foreign organizations, and requires a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Applications must be submitted electronically by January 5, 2025, with awards contingent on available funding and merit assessed through NIH's peer-review process. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Impacts of Climate Change Across the Cancer Control Continuum," aimed at supporting innovative research on the effects of climate change on cancer risks, control, and survivorship. This R21 Exploratory/Developmental Research Grant encourages multidisciplinary studies that explore the relationship between climate change and cancer-related health disparities, necessitating collaboration with climate change experts. The grant offers a budget cap of $275,000 for a two-year project period, with applications opening on January 16, 2025, and closing on May 7, 2026. Interested applicants can find more information and application instructions at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem," aimed at supporting exploratory research projects in cancer communication. This initiative focuses on three key areas: developing new cancer communication surveillance strategies, creating rapid intervention methods, and establishing multilevel communication models to enhance cancer prevention and control efforts. The NIH emphasizes the importance of utilizing contemporary methodologies, such as social media analysis and artificial intelligence, to address misinformation and improve health literacy in cancer care. Eligible applicants can receive funding of up to $275,000 for a maximum duration of two years, with applications due by September 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or refer to the detailed announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-165.html.
    Impacts of climate change across the cancer control continuum (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Impacts of climate change across the cancer control continuum (R01 Clinical Trial Optional)" aimed at researching the effects of climate change on cancer risk, prevention, and survivorship. This initiative encourages innovative studies that explore how environmental changes influence cancer risks and healthcare delivery, particularly focusing on health inequities among vulnerable populations. The funding supports a maximum project period of five years with no specified budget limit, and applications can be submitted starting January 5, 2025, with deadlines extending until February 2026. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the grant opportunity titled "Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01 Clinical Trial Optional)." This initiative aims to support research projects that explore innovative cancer communication strategies across three key areas: the development of new surveillance methods, the creation of rapid intervention strategies, and the formulation of multilevel communication models that highlight bidirectional influences. The opportunity is particularly relevant in the context of enhancing cancer prevention and control efforts in an increasingly digital landscape, addressing challenges such as misinformation and health disparities. Interested applicants can apply for funding up to $500,000 per year, with applications due by September 7, 2025. For further inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional details can be found at http://grants.nih.gov/grants/guide/pa-files/PAR-22-164.html.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)" aimed at supporting innovative preclinical and early-phase clinical research in cancer diagnosis, treatment, and prevention. This grant, with a funding ceiling of $275,000 over two years, encourages exploratory studies that may involve significant risk but have the potential to lead to breakthroughs in cancer research, particularly for underserved populations. Applications will be evaluated based on their significance, innovation, and rigor, with key deadlines for submission set for January 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.